Company: CWAN
Filing Date: 2025-03-20
Form Type: 424B3
Source: 0001193125-25-058975
Chunk: 198

Company: Clearwater Analytics Holdings, Inc.
Filing Date: 2025-03-20
Form: 424B3
Chunk 198
---
 customers, technology and other partners, suppliers, vendors or governmental authorities or other third parties related thereto); provided, that no effect will be given to this clause (A) for               
 purposes of the non-contravention representation or warranty made by Enfusion or the condition to Closing to the extent relating to such representation or warranty;                                                                                      |

| (B) | the identity of Clearwater or any of its affiliates as the acquiror of Enfusion, or any facts or circumstances                                                                                                                                     
 concerning Clearwater or any of its affiliates, including any communication by any of them regarding plans, proposals or projections with respect to Enfusion, its subsidiaries or their employees; provided, that no effect will be given to this 
 clause (B) or the foregoing clause (A) for purposes of the non-contravention representation or warranty made by Enfusion or the condition to Closing to the extent relating to such representation or                                              
 warranty;                                                                                                                                                                                                                                          |

| (C) | general business, economic or political conditions, or the capital, credit, banking, debt, financial or                                                                                       
 currency markets, in the United States or elsewhere in the world, or changes therein, including changes in interest or exchange rates or any suspension of trading in securities on the NYSE; |

| (D) | general conditions in any industry in which Enfusion and its subsidiaries operate or in any specific                                               
 jurisdiction or geographic area in the United States or elsewhere in the world in which Enfusion and its subsidiaries operate, or changes therein; |

| (E) | any changes in GAAP or other accounting standards (or the enforcement or interpretation thereof) enacted after 
 the date of the Merger Agreement;                                                                              |

| (F) | any changes in applicable law (or the enforcement or interpretation thereof), including the adoption,                                                                                                                                              
 implementation, repeal, modification, reinterpretation or proposal of any applicable law (or the enforcement or interpretation thereof) by any governmental authority, or any panel or advisory body empowered or appointed thereby, in each case, 
 enacted after the date of the Merger Agreement;                                                                                                                                                                                                    |

| (G) | the taking of any action, or refraining from taking any action, in each case at the express written direction 
 of Clearwater, Acquirer, Merger Sub or Merger Sub II or as expressly required by the Merger Agreement;        |

126

| (H) | any claim, demand, or other proceeding (including any class action or derivative litigation) asserted,                                                                                                                                          
 commenced or threatened by,